Method for preparing aptamer modified liposome by using microfluidic hybrid chip

By mixing buffer, lipid organic solution and aptamer solution in the same chip by microfluidic mixing chip, the problem of cumbersome steps and uneven particle size distribution in the prior art is solved, and the problem of cumbersome steps and uneven particle size distribution in the prior art is achieved. The preparation of targeted liposomes with small particle size and uniform distribution has been promoted to the biomedical application of targeted liposomes.

CN118892418AInactive Publication Date: 2024-11-05CENT SOUTH UNIV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202410932467.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-12
Publication Date
2024-11-05
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The methods for preparing aptamers to modify liposomes in the prior art are cumbersome, with wide particle size distribution and poor repeatability, which limits the in-depth application of targeted liposomes in the field of biomedical science.

Method used

A microfluidic hybrid chip is used to achieve one-step synthesis of aptamer-modified liposomes. By mixing buffer, lipid organic solution and aptamer solution in the same chip through the fluid-focused mixing unit and the microcolumn mixing unit, the buffer, lipid organic solution and aptamer solution are controlled. body particle size and targeting.

Benefits of technology

The process time is shortened, the operation steps are reduced, and the preparation of aptamer-modified liposomes with small particle size and uniform distribution is achieved, which improves the targeting and preparation simplicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118892418A_ABST
    Figure CN118892418A_ABST
Patent Text Reader

Abstract

The invention provides a method for preparing aptamer modified lipidosome by using a micro-fluidic mixed chip. The micro-fluidic mixing chip comprises an inlet, a solution mixing unit and an outlet; the inlet comprises a buffer solution inlet, a lipid organic solution inlet and an aptamer solution inlet; the inlet is connected with an injector and a micro-injection pump through guide pipes; the solution mixing unit comprises a fluid focusing mixing unit and a micro-column mixing unit; and the outlet is connected with a product collecting device through a guide pipe. According to the microfluidic hybrid chip, one-step synthesis of the aptamer modified liposome can be realized in the same chip, so that the process time is greatly shortened, and the operation steps are reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of microfluidics and liposome preparation, and particularly relates to a method for preparing aptamer-modified liposomes by using a microfluidics mixing chip. Background Art

[0002] Liposomes are closed vesicles composed of a phospholipid bilayer structure. Liposomes can improve the solubility of encapsulated drugs, prevent chemical and biological degradation of drugs, reduce drug toxicity and side effects, and enhance drug penetration. Due to their good biocompatibility and low immunogenicity, liposomes are recognized as ideal carriers for small molecule anti-tumor drugs and gene drugs. In recent years, liposomes have been widely used in research fields such as tumor immunotherapy, photodynamic therapy, photothermal therapy, gene therapy, and multimodal molecular imaging, which is enough to illustrate the great potential of liposomes in the future medical field.

[0003] However, conventional liposomes can only use passive targeting (EPR effect) for drug delivery, and it is difficult to achieve effective enrichment at the target site. Aptamer-modified liposomes are functional liposomes modified with targeting aptamers on the surface of liposomes, which can greatly improve the targeting of liposomes. At present, the common process for preparing aptamer-modified liposomes is: first, liposomes are prepared by thin film hydration method, reverse evaporation method and other methods; then, the liposomes are mixed and incubated with aptamers. These conventional methods not only have cumbersome preparation steps, but also the liposomes produced have shortcomings such as wide particle size distribution and poor repeatability, which limits the in-depth application of targeted liposomes in the biomedical field.

[0004] Microfluidic method is a new method for preparing liposomes based on microfluidic mixing technology. Compared with conventional preparation methods, liposomes synthesized by microfluidic method have many advantages such as small particle size, uniform distribution, and simple preparation. The development of microfluidic mixing technology provides an effective opportunity for preparing liposomes with excellent performance. However, there are still few studies on the synthesis of targeted liposomes using microfluidic methods. Therefore, the development of a method for the controllable preparation of aptamer-modified liposomes using microfluidic technology is of great significance in promoting the development of targeted liposomes. Summary of the invention

[0005] In view of the problems existing in the prior art, the present invention provides a method for preparing aptamer-modified liposomes using a microfluidic mixing chip. The microfluidic mixing chip can realize a one-step synthesis of aptamer-modified liposomes in the same chip, greatly shortening the process time and reducing the operation steps.

[0006] In order to achieve the above object, the technical solution adopted by the present invention is:

[0007] A method for preparing aptamer-modified liposomes using a microfluidic mixing chip, characterized in that the method is implemented using a microfluidic mixing chip, the microfluidic mixing chip comprises an inlet, a solution mixing unit and an outlet; the inlet comprises a buffer inlet, a lipid organic solution inlet and an aptamer solution inlet; the inlet is connected to a syringe and a microinjection pump through a catheter; the solution mixing unit comprises a fluid focusing mixing unit and a microcolumn mixing unit; the outlet is connected to a product collection device through a catheter;

[0008] The method further comprises the following steps:

[0009] (1) connecting the buffer inlet, the lipid organic solution inlet and the aptamer solution inlet to corresponding syringes through catheters, and connecting the outlets to a product collection device through catheters;

[0010] (2) preparing corresponding buffer solution, lipid organic solution and aptamer solution, and dissolving water-soluble drugs in buffer solution or lipid-soluble drugs in lipid organic solution according to the solubility of the encapsulated drugs;

[0011] (3) using a microinjection pump to inject the buffer solution, the lipid organic solution, and the aptamer solution into the buffer solution inlet, the lipid organic solution inlet, and the aptamer solution inlet, respectively, at a specific flow rate;

[0012] (4) As the lipid organic solution and the buffer solution are mixed in the fluid focusing mixing unit, the organic solvent rapidly dissolves in the aqueous phase, causing the concentration of the organic solvent to decrease sharply, allowing the lipid molecules to quickly form liposomes in the buffer solution; then, the liposome solution and the aptamer solution are mixed in the microcolumn mixing unit, thereby modifying the liposome surface with an aptamer with a specific targeting function.

[0013] Preferably, the microfluidic hybrid chip is made of a photocurable resin or polymethyl methacrylate (PMMA) or polydimethylsiloxane (PDMS).

[0014] Preferably, the inner diameter of the inlet and the outlet ranges from 400 to 2000 μm, and the depth ranges from 1.5 to 5 mm.

[0015] Preferably, the microchannel of the fluid focusing and mixing unit has a width ranging from 50 to 1000 μm and a depth ranging from 50 to 1000 μm.

[0016] Preferably, the microcolumn mixing unit comprises a cylindrical microcolumn array structure, and the diameter of each cylindrical microcolumn ranges from 50 to 300 μm.

[0017] Preferably, the buffer is PBS buffer or acetate buffer, and the solvent of the lipid organic solution is ethanol or isopropanol.

[0018] Preferably, the aptamer is a thiol-modified nucleic acid aptamer with specific targeting function.

[0019] The beneficial effects of the method for preparing aptamer-modified liposomes using a microfluidic mixing chip provided by the present invention are as follows:

[0020] (1) Compared with other microfluidic chips for synthesizing liposomes, the microfluidic hybrid chip of the present invention can achieve a one-step synthesis of aptamer-modified liposomes in the same device, greatly shortening the process time and reducing the number of operation steps;

[0021] (2) By changing the flow rate ratio of the buffer solution to the lipid organic solution, the particle size of the liposomes can be controlled, thereby synthesizing aptamer-modified liposomes with different particle size distributions. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 is a schematic diagram of a system for preparing aptamer-modified liposomes using a microfluidic mixing chip according to an embodiment of the present invention;

[0023] Figure 2 is a schematic structural diagram of a microfluidic hybrid chip according to an embodiment of the present invention;

[0024] Figure 3 is a schematic structural diagram of a T-shaped fluid focusing mixing unit according to an embodiment of the present invention;

[0025] Figure 4 is a schematic structural diagram of a Y-shaped fluid focusing mixing unit according to an embodiment of the present invention;

[0026] Figure 5 is a schematic structural diagram of a microcolumn mixing unit according to an embodiment of the present invention;

[0027] Figure 6 is a transmission electron microscopy image of the aptamer-modified liposome of an embodiment of the present invention;

[0028] Figure 7 is the particle size and zeta potential result of the aptamer-modified liposomes in the embodiment of the present invention;

[0029] Wherein: 1 microinjection pump, 2 syringe, 3 catheter, 4 microfluidic mixing chip, 401 buffer inlet, 402 lipid organic solution inlet, 403 aptamer solution inlet, 404 T-shaped fluid focusing mixing unit, 405 Y-shaped fluid focusing mixing unit, 406 microcolumn mixing unit, 407 outlet, 40401 lipid organic solution channel, 40402 buffer channel, 40403 T-shaped focusing area, 40404 fluid mixing channel, 40501 liposome solution channel, 40502 aptamer solution channel, 40503 Y-shaped focusing area, 40504 fluid mixing channel, 40601 cylindrical microcolumn mixing structure, 40602 semi-cylindrical microcolumn mixing structure. DETAILED DESCRIPTION

[0030] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0031] This embodiment provides a method for preparing aptamer-modified liposomes using a microfluidic mixing chip as follows:

[0032] A method for preparing aptamer-modified liposomes, characterized in that the method is implemented using a microfluidic mixing chip, such as Figure 1 and Figure 2 As shown, a syringe 2 is installed on a microinjection pump 1, and then connected to a microfluidic mixing chip 4 through a catheter 3; the microfluidic mixing chip 4 comprises a buffer inlet 401, a lipid organic solution inlet 402, an aptamer solution inlet 403, a T-shaped fluid focusing mixing unit 404, a Y-shaped fluid focusing mixing unit 405, a microcolumn mixing unit 406 and an outlet 407. Figure 3 As shown, the T-shaped fluid focusing and mixing unit 404 is composed of a lipid organic solution channel 40401, a buffer channel 40402, a T-shaped focusing region 40403, and a fluid mixing channel 40404. The lipid organic solution channel 40401 and the buffer channel 40402 converge in the T-shaped focusing region 40403, and are further mixed in the fluid mixing channel 40404. Figure 4As shown, the Y-shaped fluid focusing and mixing unit 405 is composed of a liposome solution channel 40501, an aptamer solution channel 40502, a Y-shaped focusing region 40503, and a fluid mixing channel 40504. The liposome solution channel 40501 and the aptamer solution channel 40502 converge in the Y-shaped focusing region 40503, and are further mixed in the fluid mixing channel 40504. Figure 5 As shown, the microcolumn mixing unit 406 includes a cylindrical microcolumn structure 40601 , and a plurality of semi-cylindrical microcolumn structures 40602 are provided at the edge of the microcolumn mixing unit 406 .

[0033] The method comprises the following steps:

[0034] (1) The buffer inlet 401, the lipid organic solution inlet 402 and the aptamer solution inlet 403 are respectively connected to the corresponding syringes 2 through the conduit 3, and the outlet 407 is connected to the product collection device through the conduit 3;

[0035] (2) preparing corresponding buffer solution, lipid organic solution and aptamer solution, and dissolving water-soluble drugs in buffer solution or lipid-soluble drugs in lipid organic solution according to the solubility of the encapsulated drugs;

[0036] (3) using the microinjection pump 1 to inject the buffer solution, the lipid organic solution and the aptamer solution into the buffer solution inlet 401, the lipid organic solution inlet 402 and the aptamer solution inlet 403 at specific flow rates;

[0037] (4) As the lipid organic solution and the buffer solution are mixed in the T-shaped fluid focusing mixing unit 404, the organic solvent is rapidly dissolved in the aqueous phase, causing the concentration of the organic solvent to decrease sharply, allowing the lipid molecules to quickly form liposomes in the buffer solution; then, the liposome solution and the aptamer solution are mixed in the Y-shaped fluid focusing unit 405 and the microcolumn mixing unit 406, thereby modifying the liposome surface with an aptamer with a specific targeting function.

[0038] Preferably, the microfluidic hybrid chip is made of a photocurable resin or PMMA or PDMS.

[0039] Preferably, the inner diameter of the inlet and the outlet ranges from 400 to 2000 μm, and the depth ranges from 1.5 to 5 mm.

[0040] Preferably, the microchannel of the fluid focusing and mixing unit has a width ranging from 50 to 1000 μm and a depth ranging from 50 to 1000 μm.

[0041] Preferably, the microcolumn mixing unit comprises a cylindrical microcolumn array structure, and the diameter of each cylindrical microcolumn ranges from 50 to 300 μm.

[0042] Preferably, the buffer is PBS buffer or acetate buffer, and the solvent of the lipid organic solution is ethanol or isopropanol.

[0043] Preferably, the aptamer is a thiol-modified nucleic acid aptamer with specific targeting function.

[0044] The specific operation process of this embodiment is as follows: using microArch produced by Chongqing Mofang Precision Technology Co., Ltd. TM The S140 3D printer was used to make the microfluidic hybrid chip 4. The resin used for printing was the GR type photocurable resin produced by Chongqing Mofang Precision Technology Co., Ltd. The structural diagram of the microfluidic hybrid chip is shown in Figure 2 As shown, the length×width×height of the microfluidic mixing chip 4 is 18×10×5 mm, and the microfluidic mixing chip 4 includes a buffer inlet 401, a lipid organic solution inlet 402, an aptamer solution inlet 403, a T-shaped fluid focusing mixing unit 404, a Y-shaped fluid focusing mixing unit 405, a microcolumn mixing unit 406 and an outlet 407. The schematic diagram of the T-shaped fluid focusing mixing unit 404 is shown in FIG. Figure 3 As shown, it includes a lipid organic solution channel 40401, two buffer channels 40402, a T-shaped focusing area 40403 and a fluid mixing channel 40404. The schematic diagram of the Y-shaped fluid focusing and mixing unit 405 is shown in FIG. Figure 4 As shown, it includes a liposome solution channel 40501, two aptamer solution channels 40502, a Y-shaped focusing area 40503 and a fluid mixing channel 40504. The schematic diagram of the microcolumn mixing unit 406 is shown in FIG. Figure 5 As shown, the microcolumn mixing unit 406 is provided with a plurality of cylindrical microcolumn structures 40601 distributed in an array, and a plurality of semi-cylindrical microcolumn structures 40602 are provided on the edge. The inner diameter of the buffer inlet 401, the lipid organic solution inlet 402 and the aptamer solution inlet 403 is 1.4 mm, and the depth is 2.6 mm. The inner diameter of the outlet 407 is 1.3 mm, and the depth is 3 mm. The channel width of the T-shaped fluid focusing mixing unit 404 and the Y-shaped fluid focusing mixing unit 405 is 400 μm, and the depth is 400 μm. The length of the microcolumn mixing unit 406 is 3 mm, the width is 2 mm, and the depth is 400 μm, wherein the diameters of the cylindrical microcolumn structure 40601 and the semi-cylindrical microcolumn structure 40602 are 200 μm. The schematic diagram of the system for preparing aptamer-modified liposomes using a microfluidic mixing chip is shown as follows. Figure 1As shown, the buffer, lipid organic solution and targeting ligand solution are respectively injected into different inlets at specific flow rates using a microinjection pump 1 and a syringe 2. The buffer inlet 401, the lipid organic solution inlet 402, the aptamer solution inlet 403 and the outlet 407 are connected to the catheter 3 through AB glue, and the catheter 3 is a polytetrafluoroethylene capillary with an inner diameter of 0.8 mm and an outer diameter of 1.2 mm. Among them, the buffer inlet 401 is injected with PBS buffer with a concentration of 0.01 mol / L and a pH of 7.4, wherein the PBS buffer contains 2 mg / mL of methylene blue; the lipid organic solution inlet 402 is injected with an ethanol solution of dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylethanolamine-polyethylene glycol 2000 (DSPE-PEG2000), distearoylphosphatidylethanolamine-polyethylene glycol 2000-maleimide (DSPE-PEG2000-Maleimide), and cholesterol in a molar ratio of 70:2.5:2.5:25, and the concentration of DPPC in ethanol is 10 mmol / L; the aptamer solution inlet 403 is injected with an aptamer solution targeting programmed death ligand 1 (PD-L1) with a concentration of 10 μmol / L. The flow rate ratio of the buffer solution to the lipid organic solution was 6, and the total flow rate was 60 mL / h. The flow rate ratio of the liposome solution (buffer solution and lipid organic solution mixture) to the aptamer solution was 6, and the total flow rate was 70 mL / h. Finally, the aptamer-modified liposomes were purified by dialysis. The morphologies of the ordinary methylene blue liposomes and the aptamer-modified methylene blue liposomes were observed using a transmission electron microscope (TEM). The transmission electron microscope photos of the obtained liposomes are shown in FIG. Figure 6 As shown in FIG. 1 , it can be observed that the particle size distribution of the aptamer-modified liposomes prepared in one step using the microfluidic hybrid chip is 100-200 nm, and the size is uniform. The particle size zeta potential instrument produced by Malvern was used to test the methylene blue liposomes and the aptamer-modified methylene blue liposomes, and the results obtained are as follows: Figure 7 The test results show that the average particle size of the aptamer-modified methylene blue liposomes is slightly higher than that of the ordinary methylene blue liposomes, and the absolute value of the negative zeta potential on the surface is higher, which indicates that the aptamer has been successfully modified onto the methylene blue liposomes.

[0045] The above-described embodiments merely express the implementation methods of the present invention, but they cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that for those skilled in the art, several modifications and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention.

Claims

1. A method for preparing aptamer-modified liposomes, characterized in that: The method is implemented by using a microfluidic mixing chip, the microfluidic mixing chip comprises an inlet, a solution mixing unit and an outlet; the inlet comprises a buffer inlet, a lipid organic solution inlet and an aptamer solution inlet; the inlet is connected to a syringe and a microinjection pump through a catheter; the solution mixing unit comprises a fluid focusing mixing unit and a microcolumn mixing unit; The outlet is connected to a product collecting device via a conduit; The method further comprises the following steps: (1) connecting the buffer inlet, the lipid organic solution inlet and the aptamer solution inlet to corresponding syringes through catheters, and connecting the outlets to a product collection device through catheters; (2) preparing corresponding buffer solution, lipid organic solution and aptamer solution, and dissolving water-soluble drugs in buffer solution or lipid-soluble drugs in lipid organic solution according to the solubility of the encapsulated drugs; (3) using a microinjection pump to inject the buffer solution, the lipid organic solution, and the aptamer solution into the buffer solution inlet, the lipid organic solution inlet, and the aptamer solution inlet, respectively, at a specific flow rate; (4) As the lipid organic solution and the buffer solution are mixed in the fluid focusing mixing unit, the organic solvent is rapidly dissolved in the aqueous phase, causing the concentration of the organic solvent to decrease sharply, so that the lipid molecules quickly form liposomes in the buffer solution; then, the liposome solution and the aptamer solution are mixed in the microcolumn mixing unit, thereby modifying the liposome surface with an aptamer with a specific targeting function; The fluid focusing mixing unit comprises a T-shaped fluid focusing mixing unit and a Y-shaped fluid focusing mixing unit; the T-shaped fluid focusing mixing unit consists of a lipid organic solution channel, a buffer channel, a T-shaped focusing area and a fluid mixing channel, wherein the lipid organic solution channel and the buffer channel converge in the T-shaped focusing area and are further mixed in the fluid mixing channel; the Y-shaped fluid focusing mixing unit consists of a liposome solution channel, an aptamer solution channel, a Y-shaped focusing area and a fluid mixing channel 40504, wherein the liposome solution channel and the aptamer solution channel converge in the Y-shaped focusing area and are further mixed in the fluid mixing channel; the microcolumn mixing unit comprises a cylindrical microcolumn structure array, and a plurality of semi-cylindrical microcolumn structures are provided at the edge of the microcolumn mixing unit.

2. A method for preparing aptamer-modified liposomes according to claim 1, characterized in that: The microfluidic mixing chip is made of photocurable resin or polymethyl methacrylate or polydimethylsiloxane; the inner diameter range of the inlet and outlet is 400-2000μm, and the depth range is 1.5-5mm; the channel width range of the fluid focusing mixing unit is 50-1000μm, and the channel depth range is 50-1000μm; the diameter range of the cylindrical microcolumn is 50-300μm.

3. A method for preparing aptamer-modified liposomes according to claim 1, characterized in that: The buffer is PBS buffer or acetate buffer, and the solvent of the lipid organic solution is ethanol or isopropanol.

4. The method for preparing aptamer-modified liposomes according to claim 1, characterized in that: The aptamer is a thiol-modified nucleic acid aptamer with specific targeting function.

Citation Information

Patent Citations

  • Microfluidic mixing device and method for preparing targeted lipidosome in one step by using microfluidic mixing device

    CN115253835A

  • Double-emulsion microcapsule wrapped by nano-particle film and preparation method of double-emulsion microcapsule

    CN118105909A

  • Magnetic separation micro-fluidic chip

    CN216639511U

  • Micro-channel and micro-fluidic mixed chip

    CN217368449U

  • Microfluidic Liposome Synthesis, Purification and Active Drug Loading

    US20150115488A1